RxDoctor Payments Data

Veena Wadhwa, MD

Internal Medicine · Jamaica, NYNPI 1952473886

Payments from drug & device makers

$1,311in general payments, 2019–2025

Across 39 payments — averaging $33.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$257
  • GSK$247
  • Lilly USA, LLC$243
  • E.r. Squibb & Sons, L.L.C.$147
  • Exact Sciences$104
  • Gilead$84
  • plus $230 from 7 others

What the payments were for

  • Food & beverage$1,311100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,311 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$18,804
Medicare patients
35
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$48,644
JanuviaSitagliptin Phosphate46$46,581
JardianceEmpagliflozin50$37,711
EliquisApixaban33$35,388
TrulicityDulaglutide22$32,696
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$15,698
Breo ElliptaFluticasone/Vilanterol29$10,577
FarxigaDapagliflozin Propanediol14$9,931
Incruse ElliptaUmeclidinium Bromide23$7,425
Lactulose37$6,412
SymbicortBudesonide/Formoterol Fumarate23$5,790
Tavaborole14$4,350
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$4,280
Diclofenac Sodium50$3,262
Albuterol Sulfate HfaAlbuterol Sulfate93$2,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$257$48,64444 claims
MerckJanuvia$42$46,58146 claims
Boehringer IngelheimJardiance$31$37,71150 claims
PfizerEliquis$52$35,38833 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$247$33,70078 claims
Lilly USA, LLCTrulicity$243$32,69622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Jamaica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →